Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 751 - 800 out of 6,641

Document Document Title
WO/2005/087787A1
The 2-fluoro-6-O-substituted ketolide derivative represented by the formula [Chemical formula 1] (1) or a pharmaceutically acceptable salt or hydrate thereof. They are new erythromycin derivatives which have potent antibacterial activity...  
WO/2005/087786A1
The invention relates to: (i) the use of osyl derivatives of genkwanin and sakuranetin having formula (I) in (a) cosmetics or dermatology and (b) therapeutics; (ii) the use of novel derivatives having formula (I) as industrial products; ...  
WO/2005/085266A2
The present invention provides macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.  
WO/2005/084689A1
The invention discloses a Radix astragli extract and production method and use thereof. Such Radix astragli extract mainly comprises astragalus saponin, organic acid and astragalus flavonoid glycoside. Such production method consists of ...  
WO/2005/085223A1
A medicine, functional food, or health food which are effective in the prevention and/or treatment of bone diseases, and contain as an active ingredient a safe flavonoid compound derived from a natural material. Also provided is a medici...  
WO/2005/085267A1
Nitrogenous fused-ring derivatives represented by the general formula (I) which exert human SGLT inhibiting activity and are useful as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postpran...  
WO2005060693A3
9-Desoxoerythromycin compounds of formula (I); wherein R1, R2, R3, R4 and R5 are as defined herein, are useful as prokinetic agents for treating disorders of gastric motility.  
WO/2005/085265A1
A nitrogenous fused-ring derivative represented by the following general formula (I), a pharmacologically acceptable salt thereof, or a prodrug of either. They have human SGLT inhibitory activity and are useful as a preventive or therape...  
WO/2005/081821A2
The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are ...  
WO2005036169A3
Fluorescent probes that have binding affinity to ribosome. The fluorescent probes are useful tools for identifying small molecules that bind to the 50S or 30S subunits of the bacterial and other ribosome inhibitors. These probes are also...  
WO2005049632A8
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of bifunctional compounds useful as therapeutic ag...  
WO/2005/080408A1
The present invention provides a method for preparing bridged macrocyclic compounds comprising the step of reacting a macrocyclic compound characterized by having at least two nucleophilic moieties with a bifunctional bridging reagent op...  
WO/2005/080549A2
The invention relates to the use of trioxacarcins as agents for treating infections caused by fungi, parasites, viruses or bacteria. The invention also relates to the novel trioxacarcin derivatives as such, to drugs containing them or th...  
WO2005054265A3
Macrolides particularly erythromycins and azithromycins, having O-mycaminosyl or O-angolosaminyl groups, particularly at the 5-position, are produced using a gene cassette comprising a combination of genes which, in an appropriate strain...  
WO/2005/075494A1
Macrolide compounds of formula (I) wherein X, R, R1, R2, R3 and R4 have the meanings as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and the use...  
WO/2005/075495A1
6-O-Substituted ketolide derivatives represented by the following general formula: [Chemical formula 1] wherein R represents hydrogen atom or a fluorine atom; or pharmaceutically acceptable salts thereof have potent antibacterial effects...  
WO2005012243A3
Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.  
WO/2005/072762A1
Provided are processes for the preparation of compositions enriched in phenolic compounds from a crude plant extract. One process includes a novel column purification step using a polymer resin that releasably absorbs the phenolic compou...  
WO/2005/072204A2
Compounds of Formula (I), and pharmaceutically acceptable salts, esters, and prodrugs thereof: (I) are disclosed, wherein A, B, D, L, X, Y, Z and R2' are described herein. The compounds exhibit antibacterial properties. The compounds of ...  
WO2005034856A3
The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic i...  
WO/2005/070918A1
The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivatives. In particular, the presen tinvention relates to processes and intermediates for the preparation of a compound of ...  
WO/2005/070427A1
The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative ther...  
WO/2005/070113A2
The present invention discloses compounds of formula (I), (II), (III), or (IV), or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: formulas (I), (II), (III), (IV), which exhibit antibacterial properties. The present ...  
WO/2005/068485A1
The present invention relates to the pharmaceutical composition and health care food comprising flavonoid compounds isolated from the extract of Sedum sarmentosum Bunge for preventing and treating hypertension. The flavonoid compounds of...  
WO/2005/067919A1
The present invention discloses compounds of formulae I, II, III or IV or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I), (II), (III), (IV), which exhibit antibacterial properties. The present invention further relat...  
WO2005027828A3
This invention features a compound of the following formula: T-(-L-C)m, T is a transportophore, L is a bond or a linker having a molecular weight up to 240 dalton, C is a non-antibiotic therapeutic agent, and m is 1, 2, 3, 4, 5, 6, 7, or...  
WO/2005/067564A2
The present invention discloses compounds of formulaes I, II, III, or IV, or a 5 racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: which exhibit antibacterial properties. The present invention further relates to pharmace...  
WO/2005/068484A1
The invention relates to complexes of specific flavonoid derivatives of formula (I), to preparations containing derivatives of this type, to corresponding methods for producting the flavonoid derivatives or preparations containing the la...  
WO2005000860A3
Compositions and methods for treatment of disease with acetylated disaccharides and analogs thereof are provided.  
WO/2005/063263A1
The invention relates to novel derivatives of morphine-6-glucuronide, the preparation method thereof and the uses of same in therapy, for example, as analgesics.  
WO2002097062A3
Recombinant DNA compounds that encode all or a portion of the narbonolide polyketide synthase are used to express recombinant polyketide synthase genes in host cells for the production of narbonolide, narbonolide derivatives, and polyket...  
WO2005049579A3
The present invention relates to immobilized N-substituted tricyclic 3-aminopyrazole compounds of Formula 1 as tools for the identification of bimolecular targets in cells of therapeutic significance, profiling the selectivity of compoun...  
WO/2005/061526A1
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formule (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compos...  
WO/2005/061525A1
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions c...  
WO/2005/060693A2
9-Desoxoerythromycin compounds of formula (I); wherein R1, R2, R3, R4 and R5 are as defined herein, are useful as prokinetic agents for treating disorders of gastric motility.  
WO/2005/061524A2
The present invention provides an efficient process for the preparation of polymorphic Form I and II of clarithromycin. The process includes drying wet clarithromycin obtained after purification in the presence of nitrogen gas and in the...  
WO/2005/054265A2
Macrolides particularly erythromycins and azithromycins, having O-mycaminosyl or O-angolosaminyl groups, particularly at the 5-position, are produced using a gene cassette comprising a combination of genes which, in an appropriate strain...  
WO/2005/054267A1
The present invention relates to compounds of formula (1) and salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 is a glycosyl moiety, hydroxyl-protected acetate derivatives thereof or ami...  
WO/2005/053650A1
An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multipar...  
WO2005011592A3
Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.  
WO2005028630A3
Disclosed herein are methods and compositions for modulation of gene expression, with single-gene specificity, in a human sized genome.  
WO/2005/049598A1
The invention relates to novel hydrosoluble yellow colouring agents of general formula (I), wherein n is equal to 0 or 1, R1 is H or an alkyl group, R2 is H, a glucose group or a xyloglucose group. A method for preparing and using the in...  
WO/2005/049632A1
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of bifunctional compounds useful as therapeutic ag...  
WO/2005/049579A2
The present invention relates to immobilized N-substituted tricyclic 3-aminopyrazole compounds of Formula 1 as tools for the identification of bimolecular targets in cells of therapeutic significance, profiling the selectivity of compoun...  
WO2005018577A3
Compounds of formula (I) and R<1>, R <2> R <3> and R <4> are as defined herein, are prokinetic agents and can be used to treat disorders of gastric motility.  
WO2005030785A3
The invention relates to novel compounds of 5-thioxylose and, preferably, 5-thioxylopyranose-type derivatives. The invention also relates to the method of preparing said compounds and to the use of same as an active principle in medicame...  
WO/2005/044834A1
A method for preparing a stabilized azithromycin composition comprising mixing azithromycin monohydrate and water to form a stabilized azithromycin composition having a water content from about 5 to about 15 weight percent, based on the ...  
WO/2005/042554A1
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of bifunctional compounds useful as therapeutic ag...  
WO/2005/042555A1
A tyrosinase activity inhibitor and an ameliorant for facial blood flow which each is highly safe; and a medicinal composition, food composition, or cosmetic preparation each containing these as active ingredients. The tyrosinase activit...  
WO/2005/039500A2
The present invention provides methods for the isolation of a new group of actinomycetes and for the identification of members of this group based on characteristic nucleotide sequences and phylogenetic analyses. This group is phylogenet...  

Matches 751 - 800 out of 6,641